Clementia Pharmaceuticals Inc (NASDAQ:CMTA) has been given a consensus broker rating score of 1.13 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and three have assigned a strong buy rating to the company.
Brokers have set a 12 month consensus price objective of $27.00 for the company and are expecting that the company will post ($0.34) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Clementia Pharmaceuticals an industry rank of 184 out of 265 based on the ratings given to its competitors.
Several brokerages have issued reports on CMTA. Wedbush restated an “outperform” rating and issued a $26.00 target price on shares of Clementia Pharmaceuticals in a report on Tuesday, November 14th. Zacks Investment Research upgraded Clementia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 30th.
Shares of Clementia Pharmaceuticals (NASDAQ CMTA) traded up $0.38 during trading hours on Thursday, reaching $12.30. The company’s stock had a trading volume of 37,109 shares, compared to its average volume of 81,571. Clementia Pharmaceuticals has a 12 month low of $11.72 and a 12 month high of $20.15.
A number of large investors have recently modified their holdings of the business. J. Goldman & Co LP purchased a new stake in Clementia Pharmaceuticals in the 4th quarter valued at $488,000. Driehaus Capital Management LLC grew its holdings in shares of Clementia Pharmaceuticals by 5.2% during the 4th quarter. Driehaus Capital Management LLC now owns 862,279 shares of the company’s stock worth $16,366,000 after purchasing an additional 42,771 shares during the period. Sectoral Asset Management Inc grew its holdings in shares of Clementia Pharmaceuticals by 148.5% during the 4th quarter. Sectoral Asset Management Inc now owns 75,313 shares of the company’s stock worth $1,429,000 after purchasing an additional 45,000 shares during the period. Alps Advisors Inc. purchased a new position in shares of Clementia Pharmaceuticals during the 4th quarter worth $642,000. Finally, Victory Capital Management Inc. grew its holdings in shares of Clementia Pharmaceuticals by 12.7% during the 4th quarter. Victory Capital Management Inc. now owns 34,710 shares of the company’s stock worth $659,000 after purchasing an additional 3,920 shares during the period. Institutional investors own 73.82% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/20/zacks-clementia-pharmaceuticals-inc-cmta-receives-consensus-recommendation-of-strong-buy-from-analysts.html.
About Clementia Pharmaceuticals
Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.
Get a free copy of the Zacks research report on Clementia Pharmaceuticals (CMTA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.